Xenon Pharmaceuticals Inc
XENEHealthcare|Biotechnology|Canada
$68.94
-2.05 (-2.89%)
Tangible Book
$13.85
Ownership Breakdown
—
Institutional
—
Insider
—
Float
—
Shares Outstanding
Insider Trades (67)
| Insider | Position | Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Cannon Gillian | Director | 2026-06-05 | SELL | 1,190 | $53.14 | $63.2K |
| PATOU GARY | Director | 2026-06-05 | SELL | 1,322 | $53.14 | $70.3K |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 2026-03-13 | SELL | 1,410 | $55.23 | $77.9K |
| DiFabio Andrea | Chief Legal Officer | 2026-03-13 | SELL | 1,342 | $55.23 | $74.1K |
| MORTIMER IAN | PRESIDENT & CEO | 2026-03-13 | SELL | 7,308 | $55.23 | $403.6K |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 2026-03-10 | SELL | 2,771 | $60.11 | $166.6K |
| DiFabio Andrea | Chief Legal Officer | 2026-03-10 | SELL | 2,607 | $60.11 | $156.7K |
| MORTIMER IAN | PRESIDENT & CEO | 2026-03-10 | SELL | 281,269 | $60.32 | $16966.1K |
| MORTIMER IAN | PRESIDENT & CEO | 2026-01-02 | SELL | 40,000 | $44.43 | $1777.2K |
| MORTIMER IAN | PRESIDENT & CEO | 2025-12-08 | SELL | 25,205 | $45.33 | $1142.5K |
| MORTIMER IAN | PRESIDENT & CEO | 2025-11-28 | SELL | 97 | $45.01 | $4.4K |
| MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO | 2025-10-01 | SELL | 25,000 | $40.16 | $1004K |
| GANNON STEVEN | Director | 2025-06-05 | SELL | 3 | $30.48 | $0.1K |
| MORTIMER IAN | PRESIDENT & CEO | 2025-01-27 | SELL | 55,000 | $40.25 | $2213.8K |
| AULIN SHERRY | CFO | 2024-12-18 | SELL | 18,709 | $41.21 | $771K |
| PATOU GARY | Director | 2024-11-22 | SELL | 4,891 | $41.08 | $200.9K |
| GAROFALO ELIZABETH A. | Director | 2024-03-08 | SELL | 2,092 | $45.69 | $95.6K |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 2024-03-07 | SELL | 7,137 | $46.28 | $330.3K |
| GANNON STEVEN | Director | 2024-03-07 | SELL | 13,000 | $46.28 | $601.6K |
| PATOU GARY | Director | 2023-12-14 | SELL | 7,598 | $41.05 | $311.9K |
| PATOU GARY | Director | 2023-12-13 | SELL | 18,978 | $39.99 | $758.9K |
| Svoronos Dawn | Director | 2023-08-24 | SELL | 25,000 | $38.7 | $967.5K |
| PIMSTONE SIMON N. | Director | 2023-06-01 | SELL | 131,245 | $38.9 | $5105.4K |
| MORTIMER IAN | PRESIDENT & CEO | 2023-05-24 | SELL | 31,655 | $41.41 | $1310.8K |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 2023-03-24 | SELL | 700 | $35.01 | $24.5K |
| PIMSTONE SIMON N. | Director | 2023-03-07 | SELL | 19,232 | $36.98 | $711.2K |
| PATOU GARY | Director | 2022-11-25 | SELL | 3,994 | $34.55 | $138K |
| AULIN SHERRY | CFO | 2022-09-02 | SELL | 15,355 | $39.57 | $607.6K |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 2022-09-01 | SELL | 65,231 | $38.31 | $2499K |
| PIMSTONE SIMON N. | Director | 2022-08-16 | SELL | 177,135 | $38.25 | $6775.4K |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 2022-08-12 | SELL | 57,743 | $38.31 | $2212.1K |
| PIMSTONE SIMON N. | Director | 2022-03-08 | SELL | 54,962 | $29.28 | $1609.3K |
| PIMSTONE SIMON N. | Director | 2022-03-08 | SELL | 2,500 | $30.8 | $77K |
| EMPFIELD JAMES R. | EVP, Drug Discovery | 2022-03-07 | SELL | 51,168 | $30.63 | $1567.3K |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | 2022-03-04 | SELL | 21,710 | $30.5 | $662.2K |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 2022-01-21 | BUY | 700 | $28.81 | $20.2K |
| Von Seggern Christopher | Chief Commercial Officer | 2021-12-06 | BUY | 4,000 | $24.4 | $97.6K |
| PIMSTONE SIMON N. | Director | 2021-11-15 | SELL | 17,557 | $31.33 | $550.1K |
| PIMSTONE SIMON N. | CEO | 2020-06-01 | SELL | 8,000 | $14.16 | $113.3K |
| HOLLER FRANK A | Director | 2019-09-20 | SELL | 12,806 | $9.32 | $119.4K |
| PIMSTONE SIMON N. | CEO | 2019-09-20 | SELL | 10,395 | $9.51 | $98.9K |
| HOLLER FRANK A | Director | 2019-09-18 | SELL | 9,437 | $9.3 | $87.8K |
| AZAB MOHAMMAD | Director | 2019-09-13 | SELL | 23 | $9.31 | $0.2K |
| AZAB MOHAMMAD | Director | 2017-11-15 | BUY | 15,000 | $2.22 | $33.3K |
| AZAB MOHAMMAD | Director | 2017-09-22 | BUY | 10,000 | $2.95 | $29.5K |
| AZAB MOHAMMAD | Director | 2017-08-18 | BUY | 6,335 | $2.9 | $18.4K |
| WINQUIST RAYMOND | Head, Translational Research | 2017-08-18 | BUY | 1,000 | $3 | $3K |
| EMPFIELD JAMES R. | SVP, Drug Discovery | 2017-08-15 | BUY | 10,000 | $2.48 | $24.8K |
| BIOTECHNOLOGY VALUE FUND L P | 2017-08-15 | BUY | 60,202 | $2.61 | $157.1K | |
| Hayden Michael R | Director | 2017-08-14 | BUY | 15,000 | $2.75 | $41.3K |
| Svoronos Dawn | Director | 2017-08-14 | BUY | 50,000 | $2.82 | $141K |
| GANNON STEVEN | Director | 2017-08-11 | BUY | 15,000 | $2.82 | $42.3K |
| PATOU GARY | Director | 2017-08-10 | BUY | 7,500 | $2.78 | $20.9K |
| MORTIMER IAN | CFO & COO | 2017-08-10 | BUY | 15,000 | $2.88 | $43.2K |
| SCHELLER RICHARD H | Director | 2017-08-10 | BUY | 7,000 | $2.85 | $20K |
| PIMSTONE SIMON N. | President & CEO | 2017-08-10 | BUY | 6,000 | $2.9 | $17.4K |
| PATOU GARY | Director | 2017-08-08 | BUY | 5,000 | $3 | $15K |
| BIOTECHNOLOGY VALUE FUND L P | 2017-06-27 | BUY | 85,461 | $4 | $341.8K | |
| BIOTECHNOLOGY VALUE FUND L P | 2017-06-27 | BUY | 85,461 | $3.04 | $259.8K | |
| BIOTECHNOLOGY VALUE FUND L P | 2017-06-22 | BUY | 20,411 | $4 | $81.6K | |
| BIOTECHNOLOGY VALUE FUND L P | 2017-06-19 | BUY | 26,408 | $3.84 | $101.4K | |
| BIOTECHNOLOGY VALUE FUND L P | 2017-06-07 | BUY | 358,698 | $3.81 | $1366.6K | |
| HOLLER FRANK A | Director | 2016-12-15 | SELL | 30,000 | $7.85 | $235.5K |
| HOLLER FRANK A | Director | 2016-08-19 | SELL | 11,938 | $7.65 | $91.3K |
| HOLLER FRANK A | Director | 2016-08-18 | SELL | 18,062 | $7.93 | $143.2K |
| MORTIMER IAN | CFO & COO | 2016-06-24 | BUY | 5,300 | $6.22 | $33K |
| GOLDBERG Y. PAUL | VP of Clinical Development | 2015-09-24 | SELL | 22,149 | $8.88 | $196.7K |
Congress & Senate Trades
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Guru Activity
1 gurus tracked